Vivaldi Capital Management LP

Position in HALO — Halozyme Therapeutics, Inc.

CIK 1682021 CHICAGO, IL

Position in HALO

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$1,583,370

-$280,099 QoQ

Shares Held

24,499

-11.5% QoQ

Ownership

0.021%

of shares outstanding

% of Portfolio

0.36%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2022

14 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Vivaldi Capital Management LP holds $3,172,478 across 4 Biotechnology names. HALO ranks #1 (49.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	HALO	Halozyme Therapeutics, Inc. This page	24,499	$1,583,370
2	GALT	Galectin Therapeutics Inc	258,584	$721,449
3	LENZ	LENZ Therapeutics, Inc.	64,052	$586,075
4	URGN	UroGen Pharma Ltd.	15,661	$281,584

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,583,370	24,499	-11.5%	Shares	Sole	2026-05-14
2025-12-31	$1,863,469	27,689	-16.5%	Shares	Sole	2026-02-13
2025-09-30	$2,430,560	33,141	-5.3%	Shares	Sole	2025-11-17
2025-06-30	$1,819,555	34,978	0.0%	Shares	Sole	2025-08-14
2025-03-31	$2,231,946	34,978	0.0%	Shares	Sole	2025-05-15
2024-12-31	$1,672,298	34,978	0.0%	Shares	Sole	2025-02-14
2024-09-30	$2,002,140	34,978	-0.3%	Shares	Sole	2024-11-14
2024-06-30	$1,836,684	35,078	0.0%	Shares	Sole	2024-08-14
2024-03-31	$1,426,973	35,078	0.0%	Shares	Sole	2024-05-15
2023-12-31	$1,296,482	35,078	0.0%	Shares	Sole	2024-02-14
2023-09-30	$1,339,979	35,078	0.0%	Shares	Sole	2023-11-14
2023-06-30	$1,265,263	35,078	+1.7%	Shares	Sole	2023-08-14
2023-03-31	$1,316,714	34,478	0.0%	Shares	Sole	2023-05-12
2022-12-31	$1,961,798	34,478	—	Shares	Sole	2023-02-14
No filing history on record for this holder in this stock.